Understanding blood clotting mechanisms in certain blood cancers
Official title: Hypoxia-Inducible Factors and Neutrophil Heterogeneity in Myeloproliferative Neoplasm-Associated Venous Thrombosis
Funded at Univ of North Carolina Chapel Hill · NIH-10895397 · Data updated 2026-11-12
This study is looking into how blood clots form in people with myeloproliferative neoplasms (a type of blood cancer) to find new ways to help prevent serious complications, and it’s designed for patients who want to learn more about their condition and potential treatments.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $141,211 |
| NIH project number | 5K08HL163485-02 |
| Project ID | NIH-10895397 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with myeloproliferative neoplasms, particularly those experiencing complications related to blood clotting.
✕Less likely to help
Patients with other types of blood disorders or those not diagnosed with myeloproliferative neoplasms may not benefit from this research.
What this research studies
This research focuses on exploring the mechanisms behind blood clotting in patients with myeloproliferative neoplasms (MPN), a type of blood cancer. The project aims to identify specific factors that contribute to thrombosis, which is a serious complication in these patients. By developing a deeper understanding of how blood cells behave in MPN, the research seeks to uncover new treatment targets that could improve patient care. The approach includes a combination of coursework, seminars, and hands-on research under the guidance of experienced mentors.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments and better management of thrombotic events in patients with myeloproliferative neoplasms.
How similar studies have gone: Previous research has shown promising results in understanding thrombotic mechanisms in related conditions, indicating that this approach has potential for success.
Where this research is happening
-
Univ of North Carolina Chapel Hill
Chapel Hill, United States Active
Researchers
- Principal investigator: Reeves, Brandi N — Univ of North Carolina Chapel Hill
- Study coordinator: Reeves, Brandi N
Related research
Other NIH-funded projects on the same topics.
-
Hypoxia-inducible factors and neutrophil diversity in blood clotting in myeloproliferative neoplasms
A physician-scientist is training over five years to uncover how low-oxygen signals and diverse neutrophils drive dangerous clots in people with myeloproliferative neoplasms, with the goal of finding new treatment targets.
-
Complement and clotting in JAK2V617F myeloproliferative neoplasms
A short, patient-friendly study will look at how a specific mutation in blood cells may trigger the body’s complement system to cause clots in people with myeloproliferative neoplasms.
-
Endothelial contribution to blood-clotting in myeloproliferative neoplasms
This project explores how the lining of blood vessels may drive dangerous clots in people with myeloproliferative neoplasms (MPNs).
-
Understanding how blood vessel cells contribute to blood clots in certain blood cancers
This study is looking at how certain cells in your blood vessels might contribute to blood clots in people with myeloproliferative neoplasms (MPNs), especially those with a specific mutation, and it aims to understand how current medications can help, with the possibility of you providing blood samples to assist in thi
-
Inherited genetic risks shaping myeloid cancer initiation
A research project at Boston Children’s Hospital is exploring how inherited genetic differences may push blood stem cells toward the start of myeloproliferative neoplasms, with potential implications for earlier detection and prevention.
-
Understanding why some myeloproliferative neoplasm patients resist interferon therapy
Researchers are studying why interferon-alpha works for some blood cancer patients but not others, by looking closely at stem cells from CALR-mutated myeloproliferative neoplasms.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.